A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) is a phase 3 interventional study registered as NCT07489495, led by Merck Sharp & Dohme with Exelixis, and recruiting on the registry. Official title: A Phase 3, Randomised, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034). Planned enrolment is 758 participants (estimated). The study started in 2026-04-09 and primary completion is expected in 2030-11-27. No results have been posted on ClinicalTrials.gov.